Protez Pharmaceuticals Inc.
This article was originally published in Start Up
The menace of drug resistant bacteria continues to grow. As Big Pharma has exited early-stage antibacterial R&D in recent years, start-ups like Protez Pharmaceuticals have filled the void.
You may also be interested in...
Ophthalmology-focused Lux Biosciences Inc. joins the ranks of recently founded in-licensers that have pulled down massive A-rounds on the back of management's track record and an in-licensed prospect. Lux's lead candidate is a calcineurin inhibitor; its initial target is uveitis.
TRACON Pharmaceuticals approach to targeted cancer therapeutics involves creating monoclonal antibodies that home in on cellular receptors that are unique to cancer cells, as well as delivery systems that target cancer tissue, in the hope of destroying cancer cells but leaving healthy tissue. Founded in early 2005, the company already has two promising in-licensed compounds in development.